Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis

• Published in: Arthritis research & therapy Vol. 25; no. 1; pp. 93 - 7
• Main Authors: Das, Priyam, Weisenfeld, Dana, Dahal, Kumar, De, Debsurya, Feathers, Vivi, Coblyn, Jonathan S., Weinblatt, Michael E., Shadick, Nancy A., Cai, Tianxi, Liao, Katherine P.
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 02.06.2023; BioMed Central; BMC
• Subjects: Abatacept - therapeutic use; Antirheumatic agents; Antirheumatic Agents - therapeutic use; Arthritis; Arthritis, Rheumatoid - drug therapy; Biologic disease-modifying anti-rheumatic drugs; Biological Products - therapeutic use; Complications and side effects; Computerized physician order entry; Disease; Drug therapy; Electronic health record; Electronic health records; Humans; Immunotherapy; Markov analysis; Markov chain; Medication prescriptions; Middle Aged; Mixture model; Monoclonal antibodies; Patient outcomes; Patients; Prescriptions; Probability; Rheumatoid arthritis; Rituximab - therapeutic use; United States; United States > US; Markov chain; Mixture model; Biologic disease-modifying anti-rheumatic drugs; Electronic health record; Medication prescriptions; Rheumatoid arthritis

Many patients with rheumatoid arthritis (RA) require a trial of multiple biologic disease-modifying anti-rheumatic drugs (bDMARDs) to control their disease. With the availability of several bDMARD options, the history of bDMARDs may provide an alternative approach to understanding subphenotypes of R...